Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT02717013
Other study ID # MTI2016-CS01
Secondary ID
Status Terminated
Phase N/A
First received March 11, 2016
Last updated February 28, 2017
Start date March 2016
Est. completion date February 2017

Study information

Verified date February 2017
Source Metabolic Technologies Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study will determine the effects of supplementing beta-hydroxy-beta-methylbutyrate (HMB) on body composition and strength changes during weight loss. When overweight and obese persons lose weight, and in particular in conjunction with dietary restrictions, muscle, bone mass, and muscle strength are also lost. HMB has been shown to preserve muscle mass and strength, and it is thought that HMB may also preserve muscle, bone, and strength during weight-loss.


Description:

Forty obese men (BMI 35-40 kg/m2,18-40 years of age) will be randomly assigned to one of four treatment interventions: 1) Calorie restricted; 2) Calorie restricted and HMB supplemented; 3) No calorie restriction; and 4) No calorie restriction and HMB-supplemented. Over the 8 week interventional period the calorie restricted group is expected to lose 3-5% of initial body weight. Anthropometric measures will be taken weekly, and dual energy x-ray absorptiometry (DXA) body composition and strength will be measured before and after 8-weeks of intervention. Blood and urine will be collected and analyzed at 0, 4, and 8 weeks. Additionally Dietary records and questionnaires concerning quality of life will be administered, and activity will be assessed using questionnaires and pedometers. Muscle biopsies will be taken before and after the 8-week study.


Recruitment information / eligibility

Status Terminated
Enrollment 10
Est. completion date February 2017
Est. primary completion date February 2017
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Male
Age group 18 Years to 40 Years
Eligibility Inclusion Criteria:

- Male

- Non-smoker

- Body mass index of 35-40 kg/m2

- Age 18-40 years

- Weight stable for past 6 months (<5 lb. change)

- In good health, free of chronic diseases/conditions that may impact measured outcomes

- Willing and able to consume a weight loss diet

- Willing and able to consume a daily nutritional supplement (in pill form)

- Available for scheduled study commitments during the 2 months of study

Exclusion Criteria:

- Smoke

- Take any cholesterol lowering or weight loss drugs or an drugs or supplements that affect blood lipids, insulin or body composition

- Weigh greater 300 pounds due to weight, size and depth limitations of equipment

- Take dietary supplements

- Have a chronic disease such as:

- Cardiopulmonary disease (e.g. recent myocardial infarction, unstable angina, stroke) or unstable disease

- Severe orthopedic/musculoskeletal or neuromuscular impairments that would contradict exercise

- Sensory impairments that interfere with following directions

- Diagnosis if dementia

- History of malignancy during the past 5 years

- Diabetes mellitus

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Placebo
Placebo capsules containing calcium lactate similar to the HMB capsules.
HMB
HMB capsules supplying 3 grams per day of calcium beta-hydroxyl-beta-methylbutyrate.

Locations

Country Name City State
United States Iowa State University Ames Iowa

Sponsors (2)

Lead Sponsor Collaborator
Metabolic Technologies Inc. Iowa State University

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Maintenance of bone mineral density Bone mineral density measured by DXA (T-score) 8 weeks
Primary Maintenance of lean mass Lean Mass measured by DXA (kg) 8 weeks
Primary Maintenance of muscle strength Muscle strength will be assessed using a Biodex Isokinetic Dynamometer (N-m) 8 weeks
Primary Maintenance of hand muscle strength Hand muscle strength will be assessed using hand grips (kg) 8 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT04101669 - EndoBarrier System Pivotal Trial(Rev E v2) N/A
Recruiting NCT04243317 - Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults N/A
Terminated NCT03772886 - Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball N/A
Completed NCT03640442 - Modified Ramped Position for Intubation of Obese Females. N/A
Completed NCT04506996 - Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2 N/A
Recruiting NCT06019832 - Analysis of Stem and Non-Stem Tibial Component N/A
Active, not recruiting NCT05891834 - Study of INV-202 in Patients With Obesity and Metabolic Syndrome Phase 2
Active, not recruiting NCT05275959 - Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI) N/A
Recruiting NCT04575194 - Study of the Cardiometabolic Effects of Obesity Pharmacotherapy Phase 4
Completed NCT04513769 - Nutritious Eating With Soul at Rare Variety Cafe N/A
Withdrawn NCT03042897 - Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer N/A
Completed NCT03644524 - Heat Therapy and Cardiometabolic Health in Obese Women N/A
Recruiting NCT05917873 - Metabolic Effects of Four-week Lactate-ketone Ester Supplementation N/A
Active, not recruiting NCT04353258 - Research Intervention to Support Healthy Eating and Exercise N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Recruiting NCT03227575 - Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control N/A
Completed NCT01870947 - Assisted Exercise in Obese Endometrial Cancer Patients N/A
Recruiting NCT06007404 - Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
Recruiting NCT05972564 - The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function Phase 1/Phase 2
Recruiting NCT05371496 - Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction Phase 2